
FDA Approves TAVR for Low-risk Patients Creates A Paradigm Shift in Cardiology
August 16, 2019 — In one coordinated move, the U.S. Food and Drug Administration (FDA) opened use of transcatheter aortic valve replacement (TAVR) to low-risk patients today. The FDA simultaneously expanded the indications for use for both the Edwards Lifesciences’ Sapien 3 valve and Medtronic’s...
TAVR is now approved for low risk patients too. As cardiac procedures continue to advance, would the demand for cardiac anesthesiolgist decline?